Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA registry

Journal of Rheumatology

Volumn 39, Issue 9, 2012, Pages 1867-1874

  Beukelman, Timothy ^a   Ringold, Sarah ^b   Davis, Trevor E ^c   Morgan DeWitt, Esi ^d   Pelajo, Christina F ^g   Weiss, Pamela F ^f   Kimura, Yukiko ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

Author keywords

Disease modifying antirheumatic drug; Drug toxicity; Juvenile idiopathic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RILONACEPT; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; CHILD; CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE REGISTRY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POLYARTHRITIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METHOTREXATE; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865703918     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120110     Document Type: Article

References (32)

1. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
2. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
3. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
4. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
5. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
6. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
7. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
8. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
9. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
10. Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Applied logistic regression. 2nd ed. New York: John Wiley & Sons; 2000:143-202.
11. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
12. Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011;50:189-95.
13. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: The Dutch national register. Ann Rheum Dis 2009;68:635-41.
14. Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:552-7.
15. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: An open label study. Ann Rheum Dis 2003;62:245-7.
16. Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: Results of an open-label prospective study. Arthritis Rheum 2005;52:548-53.
17. Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22.
18. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: Results of a multinational survey. J Rheumatol 2007;34:1146-50.
19. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24.
20. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50.
21. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
22. Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73-81.
23. Beukelman T, Guevara JP, Albert DA, Sherry DD, Burnham JM. Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: A survey of pediatric rheumatologists in the United States and Canada. J Rheumatol 2007;34:1918-24.
24. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2011 Dec 19 [E-pub ahead of print].
25. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66.
26. Huppertz HI. Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: Comment on the article by Beukelman et al. Arthritis Care Res 2011;63:1354-5; author reply 1355-6.
27. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: Suggested modification of the current screening guidelines. Rheumatology 2007;46:1015-9.
28. Grassi A, Corona F, Casellato A, Carnelli V, Bardare M. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease. J Rheumatol 2007;34:1139-45.
29. Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012;32:1121-33.
30. Hyrich KL, Lal SD, Foster HE, Thornton J, Adib N, Baildam E, et al. Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. Rheumatology 2010;49:116-22.
31. Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chedeville G, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res 2010;62:527-36.
32. Behrens EM, Beukelman T, Cron RQ. Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software. J Rheumatol 2007;34:234; author reply 234-5.